Last reviewed · How we verify
Nifedipine 30 MG
Nifedipine 30 MG, marketed by Ohio State University, is a well-established drug in the cardiovascular space. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Nifedipine 30 MG |
|---|---|
| Also known as | Nifedipine Control-release Tablets |
| Sponsor | Ohio State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation (PHASE3)
- The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PHASE4)
- Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension (PHASE4)
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy (PHASE4)
- Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine 30 MG CI brief — competitive landscape report
- Nifedipine 30 MG updates RSS · CI watch RSS
- Ohio State University portfolio CI